menu
    • menu

    Company profile for Mankind Pharma

    Mankind Mix GiF-PSE
    News
    Mankind Pharma Signs Licensing Deal With Actimed For Cachexia

    22 Nov 2025

    // PRESS RELEASE

    Mankind Pharma Q2 Profit Down 21% Amid 20% Revenue Increase

    08 Nov 2025

    // BUSINESS STD

    Mankind Pharma MD Rajeev Juneja Appointed New President Of PHDCCI

    14 Oct 2025

    // INDPHARMAPOST

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    CPhI India

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/8TC5EWpA250

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Related CompaniesRelated Companies

    About

    Mankind Pharma, came into existence in 1986. In 1991, the company was formed into a legal corporation. However, it actively started working as a fully integrated pharmaceutical company in 1995. Today, we have 11,000 employees and are heading towards a turnover of INR 50000 million. Our vast network includes 50 C&F agents and 7500+ stockists. We provide a wide range of products – Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic, Cardiovascular, Dermal, Erectile Dysfunction, and several other categories – across the nation.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mankind Pharmaindia-flag Flag
    Country
    Country
    India
    Address
    Address
    262, Okhla Industrial Estate, Phase-lll, New Delhi-110020
    Telephone
    Telephone
    +91 1146846700
    Client Email
    Email
    aparajita@mankindpharma.com
    Client Website
    Website
    https://www.mankindpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mankind-pharma-ltd/
    youtube
    YouTube
    http://www.youtube.com/@mankindpharma8266
    Twitter
    Twitter
    https://x.com/pharma_mankind
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI India

    Attending

    envelop Contact Supplier

    CPhI India

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-39644.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-64029.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-42058.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Products Under Development 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-44359.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/mankind-pharma-party-content-209.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2188

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share
    Novartis, GSK, Sanofi, BMS shell out over US$ 10 bn in dealmaking, as mid-size deals take centerstage in 2024

    Novartis, GSK, Sanofi, BMS shell out over US$ 10 bn in dealmaking, as mid-size deals take centerstage in 2024

    The world of pharmaceuticals and biotechnology continued to evolve this year with strategic alliances reshaping industry contours. With mid-size deals taking centerstage, the growth trajectory appears to be marked by a balance of both caution and calculated ambition.The deal-making environment was robust in 2023, with over 2,000 unique pharma and biotech deals totaling more than US$ 410 billion, according to the PharmaCompass database. Last year, there were over 200 mergers and acquisitions (M&As) with transactions exceeding US$ 160 billion in total value. Oncology, infections and infectious diseases, and neurology had emerged as the top three therapeutic areas for deals.PharmaCompass’ analysis indicates that the momentum has been maintained in 2024. As of August 6, the industry had seen over 1,200 unique deals valued at more than US$ 230 billion, including over 120 M&A transactions surpassing US$ 60 billion in aggregate value. While oncology maintains its lead position, neurology and immunology have gained notable traction.The one big difference is that 2024 is yet to witness a mega-deal, comparable to Pfizer’s US$ 43 billion acquisition of Seagen in 2023 or Amgen’s US$ 27.8 billion Horizon buyout announced in 2022. The largest transaction thus far has been Novo Nordisk Foundation’s US$ 16.5 billion acquisition of Catalent, a contract development and manufacturing organization (CDMO).This compilation does not include deals related to acquisition of facilities, divestment, medical devices, diagnostics and animal health. We have considered deals announced, irrespective of when these transactions were completed. For a comprehensive overview of CDMO deals and developments in 2024, please refer to our dedicated roundup.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available) Vertex buys Alpine Immune for US$ 4.9 bn; Gilead’s CymaBay buyout pays off via FDA nodAmongst the biggest acquisitions of 2024 was Vertex Pharmaceuticals’ buyout of Alpine Immune Sciences for US$ 4.9 billion. It granted Vertex access to protein-based immunotherapies, including the promising povetacicept for IgA nephropathy, a serious kidney disease.Gilead Sciences’ acquisition of CymaBay Therapeutics for US$ 4.3 billion in February secured it access to seladelpar (Livdelzi), an experimental drug that received FDA’s accelerated approval this month for primary biliary cholangitis, a liver disease that affects the bile ducts. Eli Lilly bolstered its presence in the US$ 26.65 billion inflammatory bowel disease (IBD) market by purchasing Morphic Holding for approximately US$ 3.2 billion in July. Through this deal, Lilly gained the oral IBD therapy candidate MORF-057, which will offer a more convenient dosing option compared to injectable drugs currently available in the market. Lilly sees the IBD space as a way to diversify beyond obesity.Merck expanded its ophthalmology portfolio by acquiring Eyebiotech Limited for US$ 1.3 billion (plus US$ 1.7 billion in milestone payments), obtaining Restoret for diabetic macular edema and neovascular age-related macular degeneration.Japanese drugmaker Ono Pharmaceutical acquired Deciphera Pharmaceuticals for US$ 2.4 billion, gaining Qinlock for gastrointestinal stromal tumors and vimseltinib for tenosynovial giant cell tumors. Sanofi targeted rare diseases by purchasing Inhibrx for up to US$ 2.2 billion. The acquisition gave the French drugmaker access to INBRX-101 for Alpha-1 antitrypsin deficiency, a genetic condition that can cause lung and liver damage.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available)  Novartis buys two oncology firms for their assets; J&J, Genmab join ADC bandwagonNovartis has been on a shopping spree, and has made two significant purchases this year. First, it acquired MorphoSys for € 2.7 billion (US$ 2.9 billion), thereby adding the promising bone-marrow cancer treatment pelabresib to its pipeline. Second, it announced the acquisition of Mariana Oncology for US$ 1 billion upfront (plus US$ 750 million in milestone payments), thereby expanding into radioligand therapies (RLTs) to treat cancers with high unmet need. RLTs take a targeted approach, delivering radiation to the tumor, while limiting damage to the surrounding cells.AstraZeneca entered the field of radioconjugates, which is a promising modality in the treatment of cancer, by acquiring Fusion Pharmaceuticals for US$ 2.4 billion.In January this year, Johnson & Johnson had announced the acquisition of antibody-drug-conjugate (ADC) developer Ambrx Biopharma for about US$ 2 billion. With this buyout, J&J has joined the likes of Bristol Myers Squibb, AbbVie and GSK who had entered this promising field through acquisitions last year.Similarly, Denmark’s Genmab bought ProfoundBio for US$ 1.8 billion in cash, boosting its oncology portfolio with three next-generation ADC candidates. This includes Rina-S, which recently received FDA’s fast track designation for the treatment of ovarian cancer.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available)  Novartis signs multiple collaborations; GSK, Takeda, AbbVie sign billion-dollar dealsNovartis was not just busy signing M&A deals, it also signed a bevy of collaboration agreements. For instance, Shanghai-based Argo partnered Novartis on two early-stage RNA interference candidates for cardiovascular diseases, potentially earning the former up to US$ 4.2 billion plus tiered royalties.Novartis also agreed to pay up to US$ 3 billion (including US$ 150 million upfront) to Dren Bio to use the latter’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies to treat cancer.Moreover, the Swiss drugmaker expanded its peptide discovery collaboration with Japan-based PeptiDream in a deal worth over US$ 2.71 billion in milestone payments, plus an upfront payment of US$ 180 million. Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutic drugs after ADCs and Novartis is, thus far, the only big pharma with FDA-approved radioligand PDCs. GSK entered a groundbreaking partnership with Flagship Pioneering, potentially worth over US$ 7 billion, to identify and develop 10 novel drugs and vaccines. The deal, starting with respiratory and immunology drugs, involves US$ 720 million in upfront and milestone payments for each candidate. This collaboration leverages Flagship’s extensive portfolio of over 40 biopharma companies with drug development capabilities.There were two significant deals in the field of neuroscience. First, Takeda said it is paying Swiss biotech AC Immune US$ 100 million upfront with potential further payments of US$ 2.1 billion for an exclusive option to license global rights to an Alzheimer’s vaccine and related immunotherapies.Second, AbbVie and clinical stage biotech Gilgamesh Pharmaceuticals joined forces in a deal potentially worth over US$ 2 billion to develop a new class of psychedelic compounds for psychiatric conditions, combining AbbVie’s psychiatric expertise with Gilgamesh’s innovative neuroplastogen research platform.View Pharma & Biotech Acquisitions, Deals & Agreements in 2024 as of Aug. 6 (Free Excel Available)  Our viewDuring this year, companies like Novartis (with US$ 16.8 billion), GSK (US$ 14.5 billion), Sanofi (US$ 11.9 billion), Bristol Myers Squibb (US$ 11.6 billion), and AbbVie (US$ 9.1 billion) have made substantial investments in acquisitions, collaborations and other forms of dealmaking.Though the deal-making environment is robust, we notice a shift towards mid-size transactions. Alongside, we notice a growing interest in areas such as ADCs, radiopharmaceuticals, and protein-based immunotherapies, underscoring their growing importance in drug development. There has also been significant interest in silencing RNA (siRNA) therapeutics, highlighting the industry's focus on novel approaches to disease treatment. With the industry focusing on cutting-edge technologies that address unmet medical needs, we feel there is little reason to fret over the size of the deals.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4181

    https://www.pharmacompass.com/radio-compass-blog/novartis-gsk-sanofi-bms-shell-out-over-us-10-bn-in-dealmaking-as-mid-size-deals-take-centerstage-in-2024

    #PharmaFlow by PHARMACOMPASS
    22 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Mankind Pharma Signs Licensing Deal With Actimed For Cachexia
    Mankind Pharma Signs Licensing Deal With Actimed For Cachexia

    22 Nov 2025

    // PRESS RELEASE

    https://actimedtherapeutics.com/news/40/54/Actimed-Therapeutics-Announces-Strategic-Licensing-Agreement-with-Mankind-Pharma.html

    PRESS RELEASE
    22 Nov 2025
    Share Share
    Mankind Pharma Q2 Profit Down 21% Amid 20% Revenue Increase
    Mankind Pharma Q2 Profit Down 21% Amid 20% Revenue Increase

    08 Nov 2025

    // BUSINESS STD

    https://www.business-standard.com/companies/news/mankind-pharma-q2fy26-profit-down-21-percent-revenue-up-20-percent-125110601947_1.html

    BUSINESS STD
    08 Nov 2025
    Share Share
    Mankind Pharma MD Rajeev Juneja Appointed New President Of PHDCCI
    Mankind Pharma MD Rajeev Juneja Appointed New President Of PHDCCI

    14 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/people/mankind-pharma-md-rajeev-juneja-appointed-new-president-of-phdcci-18002

    INDPHARMAPOST
    14 Oct 2025
    Share Share
    NPPA Fixes Retail Price Of Nine New Drug Combinations
    NPPA Fixes Retail Price Of Nine New Drug Combinations

    17 Sep 2025

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=181295&sid=1

    PHARMABIZ
    17 Sep 2025
    Share Share
    Mankind Partners with OpenAI to Embed AI in Operations
    Mankind Partners with OpenAI to Embed AI in Operations

    17 Sep 2025

    // BUSINESS STD

    https://www.business-standard.com/companies/news/mankind-joins-hands-with-openai-to-institutionalise-ai-in-operations-125091701254_1.html

    BUSINESS STD
    17 Sep 2025
    Share Share
    Mankind Pharma Initiates Ph 1 of MKP11093 After CDSCO Approval
    Mankind Pharma Initiates Ph 1 of MKP11093 After CDSCO Approval

    09 Sep 2025

    // EXPRESSPHARMA

    https://www.expresspharma.in/mankind-pharma-to-begin-phase-1-clinical-trial-of-mkp11093-receives-cdsco-approval/

    EXPRESSPHARMA
    09 Sep 2025
    Share Share

    USDMF

    read-more
    read-more

    01

    Atorvastatin Calcium Usp

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2022-01-12

    Pay. Date : 2021-11-29

    DMF Number : 34844

    Submission : 2020-06-05

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Atorvastatin Calcium Usp (process Ii...

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36365

    Submission : 2021-09-30

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Baclofen Usp

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2022-06-21

    Pay. Date : 2022-06-01

    DMF Number : 37011

    Submission : 2022-04-27

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Cilnidipine

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 39328

    Submission : 2024-05-01

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Clomipramine Hydrochloride Usp

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-08-20

    Pay. Date : 2020-07-21

    DMF Number : 34935

    Submission : 2020-07-30

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Clozapine Usp

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 37540

    Submission : 2023-02-01

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Empagliflozin

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40847

    Submission : 2025-09-30

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Empagliflozin (process Ii)

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 41404

    Submission : 2025-02-27

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Haloperidol Decanoate Usp

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-03-30

    Pay. Date : 2020-02-20

    DMF Number : 34353

    Submission : 2020-02-26

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Haloperidol Usp

    India
    arrow
    CPhI India
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothDelivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.

    Mankind Pharma

    GDUFA

    DMF Review : Complete

    Rev. Date : 2020-01-21

    Pay. Date : 2019-11-14

    DMF Number : 34190

    Submission : 2019-11-22

    Status : Active

    Type : II

    Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Mankind Pharma and get a quotation

    Mankind Pharma is a supplier offers 42 products (APIs, Excipients or Intermediates).

    Find a price of Atorvastatin bulk with DMF offered by Mankind Pharma

    Find a price of Baclofen bulk with DMF offered by Mankind Pharma

    Find a price of Cilnidipine bulk with DMF offered by Mankind Pharma

    Find a price of Clomipramine Hydrochloride bulk with DMF offered by Mankind Pharma

    Find a price of Clozapine bulk with DMF offered by Mankind Pharma

    Find a price of Empagliflozin bulk with DMF offered by Mankind Pharma

    Find a price of Haloperidol bulk with DMF offered by Mankind Pharma

    Find a price of Haloperidol Decanoate bulk with DMF offered by Mankind Pharma

    Find a price of Midodrine bulk with DMF offered by Mankind Pharma

    Find a price of Nitrofurantoin bulk with DMF offered by Mankind Pharma

    Find a price of Pantoprazole Sodium bulk with DMF offered by Mankind Pharma

    Find a price of Propranolol Hydrochloride bulk with DMF offered by Mankind Pharma

    Find a price of Ranolazine bulk with DMF offered by Mankind Pharma

    Find a price of Revefenacin bulk with DMF offered by Mankind Pharma

    Find a price of Rocuronium Bromide bulk with DMF offered by Mankind Pharma

    Find a price of Rosuvastatin Calcium bulk with DMF offered by Mankind Pharma

    Find a price of Sacubitril Sodium bulk with DMF offered by Mankind Pharma

    Find a price of Sacubitril-Valsartan bulk with DMF offered by Mankind Pharma

    Find a price of Sitagliptin Phosphate bulk with DMF offered by Mankind Pharma

    Find a price of Succinylcholine Chloride bulk with DMF offered by Mankind Pharma

    Find a price of Sugammadex Sodium bulk with DMF offered by Mankind Pharma

    Find a price of Telmisartan bulk with DMF offered by Mankind Pharma

    Find a price of Ticagrelor bulk with DMF offered by Mankind Pharma

    Find a price of Valsartan bulk with DMF offered by Mankind Pharma

    Find a price of Brivaracetam bulk offered by Mankind Pharma

    Find a price of Dydrogesterone bulk offered by Mankind Pharma

    Find a price of Ensifentrine bulk offered by Mankind Pharma

    Find a price of Etoricoxib bulk offered by Mankind Pharma

    Find a price of Fezolinetant bulk offered by Mankind Pharma

    Find a price of Lasmiditan bulk offered by Mankind Pharma

    Find a price of Latanoprostene Bunod bulk offered by Mankind Pharma

    Find a price of Lifitegrast bulk offered by Mankind Pharma

    Find a price of Netarsudil bulk offered by Mankind Pharma

    Find a price of Netarsudil Mesylate bulk offered by Mankind Pharma

    Find a price of Obeticholic Acid bulk offered by Mankind Pharma

    Find a price of Perfluorohexyloctane bulk offered by Mankind Pharma

    Find a price of Resmetirom bulk offered by Mankind Pharma

    Find a price of Semaglutide bulk offered by Mankind Pharma

    Find a price of Suzetrigine bulk offered by Mankind Pharma

    Find a price of Upadacitinib bulk offered by Mankind Pharma

    Find a price of Ursodeoxycholic Acid bulk offered by Mankind Pharma

    Find a price of Xanomeline bulk offered by Mankind Pharma

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search